logo
Share SHARE
FONT-SIZE Plus   Neg

SXC Health, Catalyst Health To Merge In $4.4 Bln Worth Cash-stock Deal

The boards of SXC Health Solutions (SXCI, SXC.TO) and Catalyst Health Solutions Inc. (CHSI) have unanimously approved a definitive merger deal, under which both companies would combine in a cash and stock transaction valued at about $4.4 billion. Pursuant to the deal, Catalyst shareholders would receive $28.00 cash and 0.6606 SXC shares for each Catalyst share, impling a purchase price of $81.02 per Catalyst share and a premium of nearly 28% based on the closing stock prices of SXC and Catalyst on April 17, 2012.

The transaction, which may close in the second half of 2012, is expected to be highly accretive to SXC's non-GAAP earnings in 2013, excluding transaction-related amortization expected to be some $200 million in the first 12 months after closing. The combined company expects to achieve about $125 million of annual cost synergies over the first 18 to 24 months after closing through improved scale and operating leverage. Also, the combined company is anticipated to incur nearly $40-45 million of transition expenses to achieve these annual synergies.

SXC's Chairman and Chief Executive, Mark Thierer, would serve as Chairman and CEO of the combined organization, and Jeff Park would be its EVP and Chief Financial Officer.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Wal-Mart Stores Inc., the world's largest retailer, reported a decline in second-quarter profit with a significant charge. Adjusted earnings topped analysts' estimates with higher comparable sales. Looking ahead, for the third quarter, the company projects earnings in line or below market view. The company also issued earnings forecast for fiscal 2018. The development of Alzheimer's drugs has been marred by a high failure rate. A U.S. study, which analyzed how the Alzheimer's clinical trials fared during the period of 2002 to 2012, revealed a failure rate of 99.6% compared to a failure rate of 81% for cancer drugs. Apple Inc. plans to invest roughly $1 billion to procure and produce original content over the next year, The Wall Street Journal reported, citing people familiar with the matter. The planned investment in Hollywood reportedly could result in as many as 10 new shows.
comments powered by Disqus
Follow RTT